Ken Griffin Impel Pharmaceuticals Inc Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$2.59 - $4.0 $94,643 - $146,168
36,542 Added 276.48%
49,759 $186,000
Q3 2022

Nov 14, 2022
BUY
$5.78 - $9.32 $76,394 - $123,182
13,217 New
13,217 $64,000

Others Institutions Holding IMPL

# of Institutions
1
Shares Held
14.4K
Call Options Held
0
Put Options Held
0
View Full List

About IMPEL PHARMACEUTICALS INC

IMPL Quotes by TradingView
  • Ticker IMPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,738,800
  • Market Cap $475K
  • Description
  • Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The c...
More about IMPL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email